ACCELERATE DIAGNOSTICS INC (AXDX) Stock Price & Overview

NASDAQ:AXDX • US00430H2013

Current stock price

0.034 USD
-0.05 (-61.36%)
At close:
0.052 USD
+0.02 (+52.94%)
After Hours:

The current stock price of AXDX is 0.034 USD. Today AXDX is down by -61.36%. In the past month the price decreased by -93.7%. In the past year, price decreased by -96.15%.

AXDX Key Statistics

52-Week Range0.031 - 2.09
Current AXDX stock price positioned within its 52-week range.
1-Month Range0.031 - 0.5899
Current AXDX stock price positioned within its 1-month range.
Market Cap
857.14K
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-2.38
Dividend Yield
N/A

AXDX Stock Performance

Today
-61.36%
1 Week
-92.71%
1 Month
-93.70%
3 Months
-97.12%
Longer-term
6 Months -98.16%
1 Year -96.15%
2 Years -99.51%
3 Years -99.44%
5 Years -99.96%
10 Years -99.98%

AXDX Stock Chart

ACCELERATE DIAGNOSTICS INC / AXDX Daily stock chart

AXDX Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to AXDX. When comparing the yearly performance of all stocks, AXDX is a bad performer in the overall market: 99.85% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AXDX Earnings

On May 22, 2025 AXDX reported an EPS of -0.38 and a revenue of 2.82M. The company beat EPS expectations (25.49% surprise) and missed revenue expectations (-8.57% surprise).

Next Earnings DateAug 6, 2025
Last Earnings DateMay 22, 2025
PeriodQ4 / 2024
EPS Reported-$0.38
Revenue Reported2.816M
EPS Surprise 25.49%
Revenue Surprise -8.57%

AXDX Forecast & Estimates

For the next year, analysts expect an EPS growth of 14.29% and a revenue growth 3.44% for AXDX


Analysts
Analysts85.71
Price TargetN/A
EPS Next Y14.29%
Revenue Next Year3.44%

AXDX Groups

Sector & Classification

Index Membership

AXDX Financial Highlights

Over the last trailing twelve months AXDX reported a non-GAAP Earnings per Share(EPS) of -2.38. The EPS increased by 35.33% compared to the year before.


Income Statements
Revenue(TTM)11.70M
Net Income(TTM)-50.05M
Industry RankSector Rank
PM (TTM) N/A
ROA -175.26%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%53.09%
Sales Q2Q%-6.97%
EPS 1Y (TTM)35.33%
Revenue 1Y (TTM)-2.97%

AXDX Ownership

Ownership
Inst Owners18.91%
Shares25.21M
Float15.55M
Ins Owners4.32%
Short Float %N/A
Short RatioN/A

About AXDX

Company Profile

AXDX logo image Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The company is headquartered in Denver, Colorado and currently employs 107 full-time employees. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for infections. The Accelerate PhenoTest BC Kit, which is the test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. The device provides identification (ID) results followed by antibiotic susceptibility testing (AST) for certain pathogenic bacteria commonly associated with or causing bacteremia. Its other products include Accelerate Pheno system and BC kit, Accelerate Arc system and BC Kit (Accelerate Arc Products), and Accelerate Wave system.

Company Info

IPO: 1993-10-27

ACCELERATE DIAGNOSTICS INC

3950 S Country Club Rd Ste 470 Bldg 3-307

Denver COLORADO 85714 US

CEO: Jack Phillips

Employees: 107

AXDX Company Website

AXDX Investor Relations

Phone: 13038638088

ACCELERATE DIAGNOSTICS INC / AXDX FAQ

Can you describe the business of ACCELERATE DIAGNOSTICS INC?

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The company is headquartered in Denver, Colorado and currently employs 107 full-time employees. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for infections. The Accelerate PhenoTest BC Kit, which is the test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. The device provides identification (ID) results followed by antibiotic susceptibility testing (AST) for certain pathogenic bacteria commonly associated with or causing bacteremia. Its other products include Accelerate Pheno system and BC kit, Accelerate Arc system and BC Kit (Accelerate Arc Products), and Accelerate Wave system.


Can you provide the latest stock price for ACCELERATE DIAGNOSTICS INC?

The current stock price of AXDX is 0.034 USD. The price decreased by -61.36% in the last trading session.


Does AXDX stock pay dividends?

AXDX does not pay a dividend.


What is the ChartMill technical and fundamental rating of AXDX stock?

AXDX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


Can you provide the PE ratio for AXDX stock?

ACCELERATE DIAGNOSTICS INC (AXDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.38).


Can you provide the market cap for ACCELERATE DIAGNOSTICS INC?

ACCELERATE DIAGNOSTICS INC (AXDX) has a market capitalization of 857.14K USD. This makes AXDX a Nano Cap stock.